The FLOT2 antibody targets flotillin-2. a conserved protein belonging to the flotillin family (FLOT1 and FLOT2), which are integral components of lipid raft microdomains in cellular membranes. Flotillins play critical roles in membrane trafficking, signal transduction, and cytoskeletal organization. FLOT2. encoded by the *FLOT2* gene, is ubiquitously expressed and associates with cholesterol-rich membrane domains, influencing endocytosis, exosome formation, and receptor-mediated signaling pathways. It is also implicated in cellular processes such as cell adhesion, migration, and membrane protein sorting.
Research has highlighted FLOT2's involvement in pathological conditions, particularly cancer. Overexpression of FLOT2 correlates with tumor progression, metastasis, and poor prognosis in various cancers, including breast, gastric, and hepatocellular carcinomas. Its role in regulating oncogenic signaling pathways (e.g., EGFR, Wnt/β-catenin) and promoting epithelial-mesenchymal transition (EMT) underscores its potential as a therapeutic target or diagnostic biomarker.
The FLOT2 antibody is widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study FLOT2 expression, localization, and interactions. It aids in elucidating FLOT2's functional mechanisms in both physiological and disease contexts. Recent studies also explore its relevance in neurological disorders and metabolic diseases, expanding its biomedical significance. Commercial FLOT2 antibodies are typically validated for specificity, ensuring reliability in experimental models, from cell lines to clinical tissue samples.